Esperion Therapeutics Stock Today
| ESPR Stock | USD 1.69 0.07 4.32% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Esperion Therapeutics is selling at 1.69 as of the 21st of March 2025; that is 4.32 percent increase since the beginning of the trading day. The stock's lowest day price was 1.6. Esperion Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2013 | Category Healthcare | Classification Health Care |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. The company has 197.85 M outstanding shares of which 28.1 M shares are currently shorted by private and institutional investors with about 9.11 trading days to cover. More on Esperion Therapeutics
Moving together with Esperion Stock
Moving against Esperion Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Esperion Stock Highlights
| CEO President | Sheldon Koenig | ||||
| Thematic Idea | Drugs (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite Total, Drugs, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEsperion Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Esperion Therapeutics' financial leverage. It provides some insight into what part of Esperion Therapeutics' total assets is financed by creditors.
| |||||
Esperion Therapeutics (ESPR) is traded on NASDAQ Exchange in USA. It is located in 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 and employs 304 people. Esperion Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 320.52 M. Esperion Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 197.85 M outstanding shares of which 28.1 M shares are currently shorted by private and institutional investors with about 9.11 trading days to cover.
Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Esperion Therapeutics Probability Of Bankruptcy
Ownership AllocationEsperion Therapeutics holds a total of 197.85 Million outstanding shares. Over half of Esperion Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Esperion Ownership Details
Esperion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nuveen Asset Management, Llc | 2024-12-31 | 3.1 M | |
| Indaba Capital Management, Llc | 2024-12-31 | 3 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.8 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 2.5 M | |
| Rhenman Partners Asset Management Ab | 2024-12-31 | 1.9 M | |
| Citadel Advisors Llc | 2024-12-31 | 1.8 M | |
| Bank Of America Corp | 2024-12-31 | 1.6 M | |
| Northern Trust Corp | 2024-12-31 | 1.5 M | |
| Woodline Partners Lp | 2024-12-31 | 1.5 M | |
| Wasatch Advisors Lp | 2024-12-31 | 24.5 M | |
| Blackrock Inc | 2024-12-31 | 14.2 M |
Esperion Therapeutics Historical Income Statement
Esperion Stock Against Markets
Esperion Therapeutics Corporate Management
| Benjamin JD | General Secretary | Profile | |
| Benjamin MBA | Chief Officer | Profile | |
| Glenn Brame | Chief Officer | Profile | |
| Tiffany MBA | Associate Communications | Profile | |
| Ben MBA | Chief Officer | Profile | |
| Betty Swartz | Chief Officer | Profile |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.